CN102725399B - 制备多能干细胞的材料和方法 - Google Patents
制备多能干细胞的材料和方法 Download PDFInfo
- Publication number
- CN102725399B CN102725399B CN200980162975.1A CN200980162975A CN102725399B CN 102725399 B CN102725399 B CN 102725399B CN 200980162975 A CN200980162975 A CN 200980162975A CN 102725399 B CN102725399 B CN 102725399B
- Authority
- CN
- China
- Prior art keywords
- cell
- cells
- ips
- somatocyte
- tissue
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0696—Artificially induced pluripotent stem cells, e.g. iPS
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/80—Undefined extracts from animals
- C12N2500/84—Undefined extracts from animals from mammals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/02—Coculture with; Conditioned medium produced by embryonic cells
- C12N2502/025—Coculture with; Conditioned medium produced by embryonic cells extra-embryonic cells, e.g. amniotic epithelium, placental cells, Wharton's jelly
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/09—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from epidermal cells, from skin cells, from oral mucosa cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/13—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells
- C12N2506/1307—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from connective tissue cells, from mesenchymal cells from adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0603—Embryonic cells ; Embryoid bodies
- C12N5/0606—Pluripotent embryonic cells, e.g. embryonic stem cells [ES]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
Abstract
Description
Claims (9)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2009/075733 WO2011072461A1 (en) | 2009-12-18 | 2009-12-18 | Materials and methods for generating pluripotent stem cells |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102725399A CN102725399A (zh) | 2012-10-10 |
CN102725399B true CN102725399B (zh) | 2015-03-11 |
Family
ID=44166743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200980162975.1A Active CN102725399B (zh) | 2009-12-18 | 2009-12-18 | 制备多能干细胞的材料和方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US9234179B2 (zh) |
EP (1) | EP2513297B1 (zh) |
JP (1) | JP5745533B2 (zh) |
CN (1) | CN102725399B (zh) |
WO (1) | WO2011072461A1 (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101880649B (zh) * | 2009-05-05 | 2012-09-05 | 中国福利会国际和平妇幼保健院 | 一种干细胞培养方法 |
WO2014058080A1 (ja) * | 2012-11-30 | 2014-04-17 | 独立行政法人理化学研究所 | 体細胞のリプログラミングを亢進させる方法、及び細胞作製キット |
EP3613846A1 (en) | 2013-05-22 | 2020-02-26 | The Regents of the University of California | Pluripotent human adipose adult stem cells: isolation, characterization and clinical implications |
CN104371970B (zh) * | 2013-08-15 | 2017-08-04 | 协和华东干细胞基因工程有限公司 | 一种用于培养人羊膜上皮细胞的培养基 |
JP6698626B2 (ja) | 2014-08-04 | 2020-05-27 | ユニバーシティ・オブ・カンザス | 哺乳動物多能性幹細胞、それらの調製のための方法、およびその使用 |
CN104830752B (zh) * | 2015-03-05 | 2018-05-22 | 中国农业大学 | 一种猪胎儿成纤维细胞的单细胞培养方法 |
CN110090228A (zh) * | 2018-04-18 | 2019-08-06 | 浙江大学 | 人羊膜上皮细胞在自身免疫性疾病中的治疗用途 |
CN112410373A (zh) * | 2020-11-27 | 2021-02-26 | 同济大学 | 一种从人羊膜上皮细胞建立诱导性多能干细胞的方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1589126A (zh) * | 2001-11-19 | 2005-03-02 | 阿姆尼奥泰克股份有限公司 | 角膜上皮样片材及其制造方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995002698A1 (en) | 1993-07-12 | 1995-01-26 | Life Technologies, Inc. | Composition and methods for transfecting eukaryotic cells |
US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
US5919449A (en) | 1995-05-30 | 1999-07-06 | Diacrin, Inc. | Porcine cardiomyocytes and their use in treatment of insufficient cardiac function |
US6051429A (en) | 1995-06-07 | 2000-04-18 | Life Technologies, Inc. | Peptide-enhanced cationic lipid transfections |
US6090622A (en) | 1997-03-31 | 2000-07-18 | The Johns Hopkins School Of Medicine | Human embryonic pluripotent germ cells |
DK1007631T4 (da) | 1997-07-14 | 2009-04-27 | Osiris Therapeutics Inc | Hjertemuskelregeneration ved anvendelse af mesenkymale stamceller |
US5968829A (en) | 1997-09-05 | 1999-10-19 | Cytotherapeutics, Inc. | Human CNS neural stem cells |
WO2008002329A2 (en) * | 2006-05-17 | 2008-01-03 | Tissuetech, Inc. | Isolation and expansion of animal cells in cell cultures |
-
2009
- 2009-12-18 US US13/516,530 patent/US9234179B2/en not_active Expired - Fee Related
- 2009-12-18 EP EP09852199.0A patent/EP2513297B1/en not_active Not-in-force
- 2009-12-18 CN CN200980162975.1A patent/CN102725399B/zh active Active
- 2009-12-18 WO PCT/CN2009/075733 patent/WO2011072461A1/en active Application Filing
- 2009-12-18 JP JP2012543441A patent/JP5745533B2/ja not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1589126A (zh) * | 2001-11-19 | 2005-03-02 | 阿姆尼奥泰克股份有限公司 | 角膜上皮样片材及其制造方法 |
Non-Patent Citations (2)
Title |
---|
Induction of pluripotent stem cells from mouse embryonic and adult fibroblasts by defined factors;Kazutoshi Takahashi et al;《Cell》;20060825;第126卷;663-676 * |
人角膜缘干细胞初步建系研究;文道源等;《赣南医学院学报》;20040228;第24卷(第1期);4-7 * |
Also Published As
Publication number | Publication date |
---|---|
EP2513297B1 (en) | 2016-09-21 |
JP2013514059A (ja) | 2013-04-25 |
EP2513297A4 (en) | 2013-07-31 |
US20120269782A1 (en) | 2012-10-25 |
EP2513297A1 (en) | 2012-10-24 |
JP5745533B2 (ja) | 2015-07-08 |
WO2011072461A1 (en) | 2011-06-23 |
US9234179B2 (en) | 2016-01-12 |
CN102725399A (zh) | 2012-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102725399B (zh) | 制备多能干细胞的材料和方法 | |
Cai et al. | Generation of human induced pluripotent stem cells from umbilical cord matrix and amniotic membrane mesenchymal cells | |
Aasen et al. | Efficient and rapid generation of induced pluripotent stem cells from human keratinocytes | |
Shahbazi et al. | Conversion of human fibroblasts to stably self-renewing neural stem cells with a single zinc-finger transcription factor | |
Moad et al. | A novel model of urinary tract differentiation, tissue regeneration, and disease: reprogramming human prostate and bladder cells into induced pluripotent stem cells | |
Cheng et al. | Porcine induced pluripotent stem cells require LIF and maintain their developmental potential in early stage of embryos | |
Anchan et al. | Amniocytes can serve a dual function as a source of iPS cells and feeder layers | |
EP2658965B1 (en) | Method of generating induced pluripotent stem cells and differentiated cells | |
Slamecka et al. | Non-integrating episomal plasmid-based reprogramming of human amniotic fluid stem cells into induced pluripotent stem cells in chemically defined conditions | |
Kwon et al. | Generation of leukemia inhibitory factor-dependent induced pluripotent stem cells from the Massachusetts General Hospital miniature pig | |
Jiang et al. | Human transgene-free amniotic-fluid-derived induced pluripotent stem cells for autologous cell therapy | |
Ohmine et al. | Induced pluripotent stem cells from GMP-grade hematopoietic progenitor cells and mononuclear myeloid cells | |
CN101984050B (zh) | 用于产生诱导多能干细胞(iPS)的细胞类型及其制备方法和应用 | |
EP2481795A1 (en) | Method of generating induced pluripotent stem cells and differentiated cells | |
Matsumura et al. | Establishment of integration-free induced pluripotent stem cells from human recessive dystrophic epidermolysis bullosa keratinocytes | |
Cheng et al. | Kinetic analysis of porcine fibroblast reprogramming toward pluripotency by defined factors | |
Tai et al. | Generation of Arbas Cashmere goat induced pluripotent stem cells through fibroblast reprogramming | |
Nordin et al. | Induced pluripotent stem cells: history, properties and potential applications | |
Sfougataki et al. | Reprogramming of bone marrow derived mesenchymal stromal cells to human induced pluripotent stem cells from pediatric patients with hematological diseases using a commercial mRNA kit | |
WO2012165740A1 (en) | Composition for improving dedifferentiation of cells and method for producing inducted pluripotent stem cells using the same | |
AU2564100A (en) | Pluripotential cells-1 | |
AU2021106553A4 (en) | Modification method for MFS Patient-specific Induced Pluripotent Stem Cells | |
Kang et al. | Adipose stromal cells are a more efficient source than adipose stem cells in retrovirus-mediated iPS induction | |
JP2023090959A (ja) | 幹細胞の製造方法、及び癌細胞化のリスク低減方法 | |
Mohamed | Generation and Characterization of Clinical Grade Induced Pluripotent Stem Cells (iPSCs) from Human Umbilical Cord Tissue Mesenchymal Stromal Cells (CT-MSCs) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C53 | Correction of patent for invention or patent application | ||
CB02 | Change of applicant information |
Address after: 200333 building 4, building 879, Lane 15, Zhongjiang Road, Shanghai, Putuo District Applicant after: SINO-AMERICAN ICELL (SHANGHAI) BIOTECHNOLOGY CO., LTD. Applicant after: Shanghai United Stem Cell Technology Co., Ltd. Address before: 200333 building 4, building 879, Lane 15, Zhongjiang Road, Shanghai, Putuo District Applicant before: Cell-star Biological Technology (Shanghai) Co., Ltd. Applicant before: Guolian (Shanghai) Biotechnology Research Co., Ltd. |
|
COR | Change of bibliographic data |
Free format text: CORRECT: APPLICANT; FROM: ZHONGMEI SAIAO (SHANGHAI) BIOTECHNOLOGY CO., LTD. TO: SHANGHAI CICELL BIOTECHNOLOGY CO., LTD. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20171016 Address after: 200333 building 4, building 879, Lane 15, Zhongjiang Road, Shanghai, Putuo District Co-patentee after: Beijing victory Biotechnology Co., Ltd. Patentee after: SINO-AMERICAN ICELL (SHANGHAI) BIOTECHNOLOGY CO., LTD. Co-patentee after: Guangzhou victory Biotechnology Co., Ltd. Co-patentee after: Chongqing United Stem Cell Technology Co., Ltd. Co-patentee after: Xuzhou cell Medical Co., Ltd. Co-patentee after: Shanghai United Stem Cell Technology Co., Ltd. Address before: 200333 building 4, building 879, Lane 15, Zhongjiang Road, Shanghai, Putuo District Co-patentee before: Shanghai United Stem Cell Technology Co., Ltd. Patentee before: SINO-AMERICAN ICELL (SHANGHAI) BIOTECHNOLOGY CO., LTD. |
|
TR01 | Transfer of patent right |